BTIG analyst Justin Zelin downgraded Kura Oncology (KURA) to Neutral from Buy without a price target The firm cites a lack of clarity and competitive differentiation around the safety and efficacy of ziftomenib in the KOMET-001 readout for the downgrade. BTIG sees limited upside in Kura shares in the next 12 months given the company’s recent transaction with Kyowa Kirin (KYKOY) for 50-50 profit share in the U.S., the company’s second-to-market positioning, and “unclear differentiation to date” relative to first-in-class and FDA approved Syndax’s revumenib.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology price target raised to $40 from $37 at H.C. Wainwright
- Closing Bell Movers: Semis down sharply after results
- Kura, Kyowa Kirin announce KOMET-001 results, FDA feedback for trial designs
- Kura Oncology price target lowered to $10 from $18 at Scotiabank
- Kura Oncology Announces Leadership Changes and Appointments